Cantargia Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 23

Employees

  • Stock Symbol
  • CANTA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.13
  • (As of Thursday Closing)

Cantargia General Information

Description

Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Scheelevägen 27
  • 223 63 Lund
  • Sweden
+46 046-275
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Scheelevägen 27
  • 223 63 Lund
  • Sweden
+46 046-275

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cantargia Stock Performance

As of 19-Nov-2026, Cantargia’s stock price is $0.13. Its current market cap is $35.5M with 282M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.13 $0.13 $0.13 - $0.73 $35.5M 282M 1.56M $0.07

Cantargia Financials Summary

As of 30-Jun-2026, Cantargia has a trailing 12-month revenue of $33.9M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 28,351 76,346 22,770 48,667
Revenue 33,884 32,235 0 0
EBITDA 17,950 15,536 (15,416) (26,422)
Net Income 17,874 14,960 (15,285) (26,345)
Total Assets 31,666 32,239 15,446 22,385
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cantargia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cantargia‘s full profile, request access.

Request a free trial

Cantargia Patents

Cantargia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024231251-A1 Anti-il1rap antibodies Inactive 05-May-2023
GB-202105933-D0 Anti-il1rap antibody Inactive 26-Apr-2021
CA-3202942-A1 Anti-il1rap antibody Pending 23-Dec-2020
WO-2022136569-A1 Anti-il1rap antibody Inactive 23-Dec-2020
EP-3837283-A1 Anti-il1rap antibody compositions Active 16-Aug-2018 C07K16/2866
To view Cantargia’s complete patent history, request access »

Cantargia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cantargia Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cantargia‘s full profile, request access.

Request a free trial

Cantargia Investments (1)

Cantargia’s most recent deal was a Corporate Asset Purchase with Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein). The deal was made on 10-Mar-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) 10-Mar-2020 Corporate Asset Purchase Buildings and Property
To view Cantargia’s complete investments history, request access »

Cantargia ESG

Risk Overview

Risk Rating

Updated April, 30, 2023

35.07 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 435

Rank

Percentile

To view Cantargia’s complete esg history, request access »

Cantargia FAQs

  • When was Cantargia founded?

    Cantargia was founded in 2009.

  • Where is Cantargia headquartered?

    Cantargia is headquartered in Lund, Sweden.

  • What is the size of Cantargia?

    Cantargia has 23 total employees.

  • What industry is Cantargia in?

    Cantargia’s primary industry is Drug Discovery.

  • Is Cantargia a private or public company?

    Cantargia is a Public company.

  • What is Cantargia’s stock symbol?

    The ticker symbol for Cantargia is CANTA.

  • What is the current stock price of Cantargia?

    As of 19-Nov-2026 the stock price of Cantargia is $0.13.

  • What is the current market cap of Cantargia?

    The current market capitalization of Cantargia is $35.5M.

  • What is Cantargia’s current revenue?

    The trailing twelve month revenue for Cantargia is $33.9M.

  • What is Cantargia’s annual earnings per share (EPS)?

    Cantargia’s EPS for 12 months was $0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process